Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Toxicol In Vitro. 2017 Feb 27;41:75–82. doi: 10.1016/j.tiv.2017.02.019

Figure 2. Effect of paclitaxel on irinotecan metabolism is mediated by TLR4.

Figure 2

Primary mouse hepatocytes were treated with 0.1% DMSO (vehicle) or 20 μM of paclitaxel for 24 h. After 24 h, the hepatocytes were treated with two concentrations of irinotecan, 20 μM (A); 50 μM (B) for 48 h. Supernatants collected at different time points were analyzed for levels of SN-38 by LCMS/MS. ■ indicates paclitaxel + irinotecan group in TLR4-WT; ● indicates only irinotecan in TLR4-WT; □ indicates paclitaxel + irinotecan group in TLR4-mutant; ○ indicates only irinotecan group in TLR4-mutant. The secondary order polynomial fitting describes the continuous metabolic data for different time points. n = 3 per group. All data are presented as ± S.D. (*) indicate significant difference (p < 0.05) between irinotecan and paclitaxel + irinotecan of TLR4-WT groups with respect to % induction of SN-38 levels by paclitaxel. The experiments were repeated at least thrice.